Thermostable Bivalent Filovirus Vaccine Candidate May Protect Against Ebola and Marburg Viruses | CPT PPP Coverage
Cryptopolytech (CPT) Public Press Pass (PPP)
News of the Day COVERAGE
200000048 – World Newser
•| #World |•| #Online |•| #Media |•| #Outlet |
View more Headlines & Breaking News here, as covered by cryptopolytech.com
Thermostable Bivalent Filovirus Vaccine Candidate May Protect Against Ebola and Marburg Viruses appeared on www.precisionvaccinations.com by precisionvaccinations.com.
The journal Vaccine recently published a manuscript entitled “Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.”
This publication describes the preclinical efficacy of a novel, single-vial, bivalent thermostabilized vaccine providing 100% protection in the most rigorous non-human primate challenge models against Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.
Recent outbreaks have occurred in Africa, with increased frequency in 2023.
There are currently no approved vaccines or therapeutics for either SUDV or MARV infections.
However, vaccines are available for Zaire ebolavirus (EBOV) infections in 2024, but they provide no protection against SUDV or MARV infection.
“Filoviruses such as EBOV, SUDV, and MARV are some of the most lethal viruses known, and they are endemic in areas of the world where the power supply and distribution network can be uncertain, says the World Health Organization.
A thermostabilized vaccine in a single vial format would significantly enhance any public health response to a new outbreak, at its source,” stated Axel Lehrer, Ph.D., Associate Professor, Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawai?i at M?noa, in a press release.
“Our work to date has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can then be stored for extended times at temperatures exceeding 100 degrees Fahrenheit.”
“The use of a bivalent vaccine has the potential to both prevent future infections with these pathogens and potentially mitigate future outbreak events, potentially using an accelerated dosing regimen.”
The thermostabilized filovirus vaccine program continues to advance with the support of a National Institute of Health grant and a Small Business Innovation Research grant awarded to Soligenix, Inc.
FEATURED ‘News of the Day’, as reported by public domain newswires.
View ALL Headlines & Breaking News here.
Source Information (if available)
This article originally appeared on www.precisionvaccinations.com by precisionvaccinations.com – sharing via newswires in the public domain, repeatedly. News articles have become eerily similar to manufacturer descriptions.
We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.
CPT (CryptoPolyTech) PPP (Public Press Pass) Coverage features stories and headlines you may not otherwise see due to the manipulation of mass media.
First to share? If share image does not populate, please close the share box & re-open or reload page to load the image, Thanks!